Neuralstem narrows loss in past year

Neuralstem Inc., of Rockville, which is developing products to treat central nervous system disorders with patented stem cell technology, cut its net loss in 2012 to $10.1 million, or 17 cents per share, less than the loss of $12.5 million, or 26 cents per share, that the biotherapeutic company reported for the full year of 2011.